Shionogi & Co Ltd (SGIOF) 23.1973 $SGIOF
Shionogi Inc. Enlists BuzzeoPDMA, a Cegedim Company to Support their Sample Management Compliance Programs
Business Wire - Thu Sep 04, 12:00PM CDT
BuzzeoPDMA, A Cegedim Company, today announced that Shionogi Inc. has selected BuzzeoPDMA's sample management services to help the company maintain compliance with the FDA's PDMA regulations. Shionogi Inc., the U.S.-based subsidiary of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company, focuses in the therapeutic areas of pain, women's health and cardiovascular disease.
Research and Markets: Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
Business Wire - Tue Jul 15, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbvk9b/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering.
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
DirectView Enters Into Preferred Security Provider Agreement with Legacy Construction Company of Colorado for their Existing and Future Marijuana Facility Construction Projects
PR Newswire - Wed Feb 26, 7:00AM CST
DirectView Holdings, Inc. (OTC: DIRV), a company focused on ownership and management of leading video and security technology companies, today announced that its wholly owned subsidiary DirectView Security has entered into a preferred provider agreement with Legacy Construction Company of Colorado, LLC ("Legacy"
.
Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hyperalgesia - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 07, 2:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/rrsm2z/hyperalgesia) has announced the addition of the "Hyperalgesia - Pipeline Review, H2 2013" report to their offering. 'Hyperalgesia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperalgesia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperalgesia. Scope - A snapshot of the global therapeutic scenario for Hyperalgesia. - A review of the Hyperalgesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hyperalgesia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Hyperalgesia Overview Therapeutics Development Pipeline Products for Hyperalgesia - Overview Pipeline Products for Hyperalgesia - Comparative Analysis Hyperalgesia - Therapeutics under Development by Companies Hyperalgesia - Therapeutics under Investigation by Universities/Institutes Hyperalgesia - Pipeline Products Glance Early Stage Products Hyperalgesia - Products under Development by Companies Hyperalgesia - Products under Investigation by Universities/Institutes Hyperalgesia - Companies Involved in Therapeutics Development Shionogi & Co., Ltd. Hyperalgesia - Therapeutics Assessment Drug Profiles LASSBio-873 - Drug Profile Drug For Neuropathic Pain - Drug Profile Drug For Methylglyoxal Induced Pains - Drug Profile P2X3 Receptor Antagonist - Drug Profile Protein Kinase 1 Alpha Inhibitor - Drug Profile Selective Phospholipase A2 Inhibitors - Drug Profile Hyperalgesia - Dormant Projects Companies Mentioned Shionogi & Co., Ltd. For more information visit http://www.researchandmarkets.com/research/rr...peralgesia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Rhabdomyosarcoma - Pipeline Review, H2 2013 Includes Players such as Eli Lilly and Company and Neotropix, Inc.
M2 - Wed Jan 22, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/s85dzx/rhabdomyosarcoma) has announced the addition of the "Rhabdomyosarcoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Rhabdomyosarcoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Rhabdomyosarcoma. - A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhabdomyosarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Arisaph Pharmaceuticals, Inc. -Celgene Corporation -Daiichi Sankyo Company, Limited -Eli Lilly and Company -Merrimack Pharmaceuticals, Inc. -Neotropix, Inc. -Shionogi & Co., Ltd. -Vaccinex, Inc. For more information visit http://www.researchandmarkets.com/research/s8...myosarcoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report on the International High-Growth Diagnostic Testing Markets
M2 - Mon Jan 13, 7:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3946g5/highgrowth) has announced the addition of the "2013 Report on the International High-Growth Diagnostic Testing Markets" report to their offering. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. This examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned: - A Menarini Diagnostics - Bayer Corporation - Calypte Biomedical Corporation - Denka Seiken - EY Laboratories - Enterix - Genetix - Genzyme Diagnostics - Hologic Gen Probe - Instrumentation Laboratory - Jiangnan Biotech - Johnson & Johnson - Kyowa Medex - LifeAssays AB - LifeScan - Matritech - NOVA Biomedical - OraSure - Pheromone Sciences Corporation - QIAGEN NV - Radiometer Medical - Roche Diagnostics - Shanghai SIIC Kehua Biotech - Shionogi & Co - Siemens Healthcare Diagnostics - Spectral Diagnostics - Trinity Biotech - V?samed - diaDexus For more information visit http://www.researchandmarkets.com/research/3946g5/highgrowth
Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.
M2 - Fri Jan 10, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/l3xgrw/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Angimmune LLC -Eisai Co., Ltd. -Emergent BioSolutions Inc. -Janssen Global Services, LLC -Kirin Holdings Company, Limited -Merck & Co., Inc. -National Cancer Institute -Northwestern University -OncoSec Medical Inc. -Roswell Park Cancer Institute -Shionogi & Co., Ltd. -Spectrum Pharmaceuticals, Inc. -Stanford University -University of Washington -Wake Forest University For more information visit http://www.researchandmarkets.com/research/l3...y_syndrome About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Obesity - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8nk97f/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2013" report to their offering. 'Obesity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Scope - A snapshot of the global therapeutic scenario for Obesity. - A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Obesity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Boehringer Ingelheim GmbH Shionogi & Co., Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Merck & Co., Inc. Novo Nordisk A/S Takeda Pharmaceutical Company Limited Plexxikon Inc. BioLineRx, Ltd. Ipsen S.A. Chong Kun Dang Pharmaceutical Glenmark Pharmaceuticals Ltd. GTx, Inc. Kissei Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation Norgine Limited and much more... For more information visit http://www.researchandmarkets.com/research/8nk97f/obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Thrombocytopenia - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/67bv4h/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H2 2013" report to their offering. 'Thrombocytopenia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. Scope - A snapshot of the global therapeutic scenario for Thrombocytopenia. - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocytopenia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Thrombocytopenia Overview Therapeutics Development An Overview of Pipeline Products for Thrombocytopenia Thrombocytopenia Therapeutics under Development by Companies Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Thrombocytopenia Therapeutics - Products under Development by Companies Appendix Methodology List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. GlaxoSmithKline plc BioLineRx, Ltd. Eisai Co., Ltd. Octapharma AG Ono Pharmaceutical Co., Ltd. Cleveland BioLabs, Inc. Portola Pharmaceuticals, Inc. Uni-Bio Science Group Ltd. Cellerant Therapeutics, Inc. Pharmagenesis, Inc. Bolder Biotechnology, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/67...ocytopenia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urinary Tract Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q89r4h/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2013" report to their offering. 'Urinary Tract Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Urinary Tract Infections Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Toyama Chemical Co. Ltd - Paratek Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Plethora Solutions Holdings plc - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - ConjuGon, Inc. - Osel Inc. - Pinnacle Pharmaceuticals, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/q8...nary_tract
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Neuropathic Pain - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fcxlmd/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H2 2013" report to their offering. 'Neuropathic Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathic Pain. Scope - A snapshot of the global therapeutic scenario for Neuropathic Pain. - A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuropathic Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Genzyme Corporation DURECT Corporation Kyowa Hakko Kirin Co., Ltd. Biogen Idec Inc. Allergan, Inc. Shionogi & Co., Ltd. Sanofi-Aventis AstraZeneca PLC BioDelivery Sciences International, Inc. Nektar Therapeutics MedImmune LLC Quark Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Sangamo BioSciences, Inc. XenoPort, Inc. BioLineRx, Ltd. Samyang Corporation Acorda Therapeutics, Inc. Astellas Pharma Inc. and many more... For more information visit http://www.researchandmarkets.com/research/fc...athic_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Allergic Rhinitis - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7llmpg/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2013" report to their offering. 'Allergic Rhinitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhinitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhinitis. - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Rhinitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. Boehringer Ingelheim GmbH Bausch & Lomb Incorporated Shionogi & Co., Ltd. GlaxoSmithKline plc Genentech, Inc. Nektar Therapeutics Dainippon Sumitomo Pharma Co., Ltd. Novartis AG ALK-Abello A/S Glenmark Pharmaceuticals Ltd. Mitsubishi Tanabe Pharma Corporation Ono Pharmaceutical Co., Ltd. Pfizer Inc. Teva Pharmaceutical Industries Limited Zeria Pharmaceutical Co Ltd Sun Pharmaceutical Industries Limited Revance Therapeutics, Inc. FAES Farma SA Nuvo Research Inc. Hisamitsu Pharmaceutical Co., Inc. Array BioPharma Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7l...c_rhinitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lymphoma - Pipeline Review, H2 2013 Reveals the Latest News and Deals Relating to the Products
M2 - Wed Sep 04, 9:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37s3zw/lymphoma) has announced the addition of the "Lymphoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Lymphoma. - A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Genzyme Corporation - Biogen Idec Inc. - Allergan, Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Quark Pharmaceuticals, Inc. - Daiichi Sankyo Company, Ltd - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sangamo BioSciences, Inc. - XenoPort, Inc. - BioLineRx, Ltd. - LEO Pharma A/S - Pfizer Inc. - Sun Pharmaceutical Industries Limited - VistaGen Therapeutics , Inc. - Palau Pharma S.A - Snowdon Inc. - Neurotune AG - AngioChem Inc. - PharmEste - Trevena, Inc. - MediProPharma, Inc. - Celtic Pharmaceutical Holdings L.P. - Vichem Chemie Research Ltd. - RaQualia Pharma Inc. - Naurex, Inc. - Cytogel Pharma, LLC For more information visit http://www.researchandmarkets.com/research/37s3zw/lymphoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hypertension - Pipeline Review, H2 2013
M2 - Wed Sep 04, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9d89hf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension. Scope - A snapshot of the global therapeutic scenario for Hypertension. - A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hypertension pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Hypertension. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - AFFiRiS - Ache Laboratorios Farmaceuticos - Ahn-Gook Pharmaceutical Co. - Anacor Pharmaceuticals - AngioDesign - BioLineRx - Biocon Limited - Biolink Group - Cellceutix Corporation - Chong Kun Dang Pharmaceutical - Choongwae Pharma Corp - Compugen - Cytokinetics - DONGKOOK Pharmaceutical Co. - Daewoong Pharmaceutical Co. - Daiichi Sankyo Company - DiaMedica - Diakron Pharmaceuticals - GlaxoSmithKline - Hanall Pharmaceutical Co. - INNOPHARMAX - IntelGenx Technologies Corp. - Kotobuki Pharmaceutical Co. - LG Life Sciences - Medivir - Merck & Co. - MicroDose Therapeutx - miRagen Therapeutics - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Panacea Biotec - QUANTUM GENOMICS Corp. - Samyang Corporation - Sanofi-Aventis - Shionogi & Co. - Sihuan Pharmaceutical Holdings Group - Takeda Pharmaceutical Company - Torrent Pharmaceuticals - Vicore Pharma - Yuhan Corporation - vasopharm For more information visit http://www.researchandmarkets.com/research/9d...pertension About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pediatric Cancer - Pipeline Review, H2 2013
M2 - Wed Sep 04, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hd2jzg/pediatric_cancer) has announced the addition of the "Pediatric Cancer - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Pediatric Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pediatric Cancer. Scope - A snapshot of the global therapeutic scenario for Pediatric Cancer. - A review of the Pediatric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pediatric Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Pediatric Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pediatric Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - AEterna Zentaris - Ambit Biosciences Corporation - Antigenics - Astellas Pharma - Boehringer Ingelheim - Crusade Laboratories - Eisai - Incyte Corporation - Innogene Kalbiotech - Lixte Biotechnology Holdings - Marshall Edwards - PharmaMar - Polaris Group - Sanofi-Aventis - Shionogi & Co. - Spectrum Pharmaceuticals - Stemline Therapeutics - SuperGen For more information visit http://www.researchandmarkets.com/research/hd...ric_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Alzheimer's Disease Report - Pipeline Review
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d9h2c7/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2013" report to their offering. 'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. Scope - A snapshot of the global therapeutic scenario for Alzheimer's Disease. - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Alzheimer's Disease Therapeutics Development - Click the link below to view the full list of companies - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - United Biomedical, Inc. - Taisho Pharmaceutical Co., Ltd. - Euroscreen S.A. - Applied NeuroSolutions, Inc. - Avineuro Pharmaceuticals, Inc. - Panacea Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - Novartis AG - Isotechnika Pharma Inc. - Samyang Corporation - Aphios Corporation - Alzhyme Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - H Lundbeck A/S - Jeil Pharmaceutical Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier For more information visit http://www.researchandmarkets.com/research/d9h2c7/alzheimers
Shionogi Inc. Enlists BuzzeoPDMA, a Cegedim Company to Support their Sample Management Compliance Programs
Business Wire - Thu Sep 04, 12:00PM CDT
BuzzeoPDMA, A Cegedim Company, today announced that Shionogi Inc. has selected BuzzeoPDMA's sample management services to help the company maintain compliance with the FDA's PDMA regulations. Shionogi Inc., the U.S.-based subsidiary of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company, focuses in the therapeutic areas of pain, women's health and cardiovascular disease.
Research and Markets: Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
Business Wire - Tue Jul 15, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbvk9b/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering.
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
DirectView Enters Into Preferred Security Provider Agreement with Legacy Construction Company of Colorado for their Existing and Future Marijuana Facility Construction Projects
PR Newswire - Wed Feb 26, 7:00AM CST
DirectView Holdings, Inc. (OTC: DIRV), a company focused on ownership and management of leading video and security technology companies, today announced that its wholly owned subsidiary DirectView Security has entered into a preferred provider agreement with Legacy Construction Company of Colorado, LLC ("Legacy"
. Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hyperalgesia - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 07, 2:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/rrsm2z/hyperalgesia) has announced the addition of the "Hyperalgesia - Pipeline Review, H2 2013" report to their offering. 'Hyperalgesia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperalgesia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperalgesia. Scope - A snapshot of the global therapeutic scenario for Hyperalgesia. - A review of the Hyperalgesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hyperalgesia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Hyperalgesia Overview Therapeutics Development Pipeline Products for Hyperalgesia - Overview Pipeline Products for Hyperalgesia - Comparative Analysis Hyperalgesia - Therapeutics under Development by Companies Hyperalgesia - Therapeutics under Investigation by Universities/Institutes Hyperalgesia - Pipeline Products Glance Early Stage Products Hyperalgesia - Products under Development by Companies Hyperalgesia - Products under Investigation by Universities/Institutes Hyperalgesia - Companies Involved in Therapeutics Development Shionogi & Co., Ltd. Hyperalgesia - Therapeutics Assessment Drug Profiles LASSBio-873 - Drug Profile Drug For Neuropathic Pain - Drug Profile Drug For Methylglyoxal Induced Pains - Drug Profile P2X3 Receptor Antagonist - Drug Profile Protein Kinase 1 Alpha Inhibitor - Drug Profile Selective Phospholipase A2 Inhibitors - Drug Profile Hyperalgesia - Dormant Projects Companies Mentioned Shionogi & Co., Ltd. For more information visit http://www.researchandmarkets.com/research/rr...peralgesia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Rhabdomyosarcoma - Pipeline Review, H2 2013 Includes Players such as Eli Lilly and Company and Neotropix, Inc.
M2 - Wed Jan 22, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/s85dzx/rhabdomyosarcoma) has announced the addition of the "Rhabdomyosarcoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Rhabdomyosarcoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhabdomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Rhabdomyosarcoma. - A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhabdomyosarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Arisaph Pharmaceuticals, Inc. -Celgene Corporation -Daiichi Sankyo Company, Limited -Eli Lilly and Company -Merrimack Pharmaceuticals, Inc. -Neotropix, Inc. -Shionogi & Co., Ltd. -Vaccinex, Inc. For more information visit http://www.researchandmarkets.com/research/s8...myosarcoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report on the International High-Growth Diagnostic Testing Markets
M2 - Mon Jan 13, 7:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3946g5/highgrowth) has announced the addition of the "2013 Report on the International High-Growth Diagnostic Testing Markets" report to their offering. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. This examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned: - A Menarini Diagnostics - Bayer Corporation - Calypte Biomedical Corporation - Denka Seiken - EY Laboratories - Enterix - Genetix - Genzyme Diagnostics - Hologic Gen Probe - Instrumentation Laboratory - Jiangnan Biotech - Johnson & Johnson - Kyowa Medex - LifeAssays AB - LifeScan - Matritech - NOVA Biomedical - OraSure - Pheromone Sciences Corporation - QIAGEN NV - Radiometer Medical - Roche Diagnostics - Shanghai SIIC Kehua Biotech - Shionogi & Co - Siemens Healthcare Diagnostics - Spectral Diagnostics - Trinity Biotech - V?samed - diaDexus For more information visit http://www.researchandmarkets.com/research/3946g5/highgrowth
Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.
M2 - Fri Jan 10, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/l3xgrw/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Angimmune LLC -Eisai Co., Ltd. -Emergent BioSolutions Inc. -Janssen Global Services, LLC -Kirin Holdings Company, Limited -Merck & Co., Inc. -National Cancer Institute -Northwestern University -OncoSec Medical Inc. -Roswell Park Cancer Institute -Shionogi & Co., Ltd. -Spectrum Pharmaceuticals, Inc. -Stanford University -University of Washington -Wake Forest University For more information visit http://www.researchandmarkets.com/research/l3...y_syndrome About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Obesity - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8nk97f/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2013" report to their offering. 'Obesity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Scope - A snapshot of the global therapeutic scenario for Obesity. - A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Obesity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Boehringer Ingelheim GmbH Shionogi & Co., Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Merck & Co., Inc. Novo Nordisk A/S Takeda Pharmaceutical Company Limited Plexxikon Inc. BioLineRx, Ltd. Ipsen S.A. Chong Kun Dang Pharmaceutical Glenmark Pharmaceuticals Ltd. GTx, Inc. Kissei Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation Norgine Limited and much more... For more information visit http://www.researchandmarkets.com/research/8nk97f/obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Thrombocytopenia - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/67bv4h/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H2 2013" report to their offering. 'Thrombocytopenia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. Scope - A snapshot of the global therapeutic scenario for Thrombocytopenia. - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocytopenia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Thrombocytopenia Overview Therapeutics Development An Overview of Pipeline Products for Thrombocytopenia Thrombocytopenia Therapeutics under Development by Companies Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Thrombocytopenia Therapeutics - Products under Development by Companies Appendix Methodology List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. GlaxoSmithKline plc BioLineRx, Ltd. Eisai Co., Ltd. Octapharma AG Ono Pharmaceutical Co., Ltd. Cleveland BioLabs, Inc. Portola Pharmaceuticals, Inc. Uni-Bio Science Group Ltd. Cellerant Therapeutics, Inc. Pharmagenesis, Inc. Bolder Biotechnology, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/67...ocytopenia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urinary Tract Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q89r4h/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2013" report to their offering. 'Urinary Tract Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Urinary Tract Infections Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Toyama Chemical Co. Ltd - Paratek Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Plethora Solutions Holdings plc - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - ConjuGon, Inc. - Osel Inc. - Pinnacle Pharmaceuticals, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/q8...nary_tract
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Neuropathic Pain - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fcxlmd/neuropathic_pain) has announced the addition of the "Neuropathic Pain - Pipeline Review, H2 2013" report to their offering. 'Neuropathic Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathic Pain. Scope - A snapshot of the global therapeutic scenario for Neuropathic Pain. - A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Neuropathic Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Genzyme Corporation DURECT Corporation Kyowa Hakko Kirin Co., Ltd. Biogen Idec Inc. Allergan, Inc. Shionogi & Co., Ltd. Sanofi-Aventis AstraZeneca PLC BioDelivery Sciences International, Inc. Nektar Therapeutics MedImmune LLC Quark Pharmaceuticals, Inc. Daiichi Sankyo Company, Ltd Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Sangamo BioSciences, Inc. XenoPort, Inc. BioLineRx, Ltd. Samyang Corporation Acorda Therapeutics, Inc. Astellas Pharma Inc. and many more... For more information visit http://www.researchandmarkets.com/research/fc...athic_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Allergic Rhinitis - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7llmpg/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2013" report to their offering. 'Allergic Rhinitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhinitis. Scope - A snapshot of the global therapeutic scenario for Allergic Rhinitis. - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Rhinitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. Boehringer Ingelheim GmbH Bausch & Lomb Incorporated Shionogi & Co., Ltd. GlaxoSmithKline plc Genentech, Inc. Nektar Therapeutics Dainippon Sumitomo Pharma Co., Ltd. Novartis AG ALK-Abello A/S Glenmark Pharmaceuticals Ltd. Mitsubishi Tanabe Pharma Corporation Ono Pharmaceutical Co., Ltd. Pfizer Inc. Teva Pharmaceutical Industries Limited Zeria Pharmaceutical Co Ltd Sun Pharmaceutical Industries Limited Revance Therapeutics, Inc. FAES Farma SA Nuvo Research Inc. Hisamitsu Pharmaceutical Co., Inc. Array BioPharma Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7l...c_rhinitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lymphoma - Pipeline Review, H2 2013 Reveals the Latest News and Deals Relating to the Products
M2 - Wed Sep 04, 9:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37s3zw/lymphoma) has announced the addition of the "Lymphoma - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Lymphoma. - A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Some of the Companies Mentioned: - Bristol-Myers Squibb Company - Genzyme Corporation - Biogen Idec Inc. - Allergan, Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Quark Pharmaceuticals, Inc. - Daiichi Sankyo Company, Ltd - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sangamo BioSciences, Inc. - XenoPort, Inc. - BioLineRx, Ltd. - LEO Pharma A/S - Pfizer Inc. - Sun Pharmaceutical Industries Limited - VistaGen Therapeutics , Inc. - Palau Pharma S.A - Snowdon Inc. - Neurotune AG - AngioChem Inc. - PharmEste - Trevena, Inc. - MediProPharma, Inc. - Celtic Pharmaceutical Holdings L.P. - Vichem Chemie Research Ltd. - RaQualia Pharma Inc. - Naurex, Inc. - Cytogel Pharma, LLC For more information visit http://www.researchandmarkets.com/research/37s3zw/lymphoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hypertension - Pipeline Review, H2 2013
M2 - Wed Sep 04, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9d89hf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension. Scope - A snapshot of the global therapeutic scenario for Hypertension. - A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hypertension pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Hypertension. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - AFFiRiS - Ache Laboratorios Farmaceuticos - Ahn-Gook Pharmaceutical Co. - Anacor Pharmaceuticals - AngioDesign - BioLineRx - Biocon Limited - Biolink Group - Cellceutix Corporation - Chong Kun Dang Pharmaceutical - Choongwae Pharma Corp - Compugen - Cytokinetics - DONGKOOK Pharmaceutical Co. - Daewoong Pharmaceutical Co. - Daiichi Sankyo Company - DiaMedica - Diakron Pharmaceuticals - GlaxoSmithKline - Hanall Pharmaceutical Co. - INNOPHARMAX - IntelGenx Technologies Corp. - Kotobuki Pharmaceutical Co. - LG Life Sciences - Medivir - Merck & Co. - MicroDose Therapeutx - miRagen Therapeutics - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Panacea Biotec - QUANTUM GENOMICS Corp. - Samyang Corporation - Sanofi-Aventis - Shionogi & Co. - Sihuan Pharmaceutical Holdings Group - Takeda Pharmaceutical Company - Torrent Pharmaceuticals - Vicore Pharma - Yuhan Corporation - vasopharm For more information visit http://www.researchandmarkets.com/research/9d...pertension About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pediatric Cancer - Pipeline Review, H2 2013
M2 - Wed Sep 04, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hd2jzg/pediatric_cancer) has announced the addition of the "Pediatric Cancer - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Pediatric Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pediatric Cancer. Scope - A snapshot of the global therapeutic scenario for Pediatric Cancer. - A review of the Pediatric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pediatric Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Pediatric Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Pediatric Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - AEterna Zentaris - Ambit Biosciences Corporation - Antigenics - Astellas Pharma - Boehringer Ingelheim - Crusade Laboratories - Eisai - Incyte Corporation - Innogene Kalbiotech - Lixte Biotechnology Holdings - Marshall Edwards - PharmaMar - Polaris Group - Sanofi-Aventis - Shionogi & Co. - Spectrum Pharmaceuticals - Stemline Therapeutics - SuperGen For more information visit http://www.researchandmarkets.com/research/hd...ric_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Alzheimer's Disease Report - Pipeline Review
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d9h2c7/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2013" report to their offering. 'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. Scope - A snapshot of the global therapeutic scenario for Alzheimer's Disease. - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Alzheimer's Disease Therapeutics Development - Click the link below to view the full list of companies - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Shionogi & Co., Ltd. - Sanofi-Aventis - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - United Biomedical, Inc. - Taisho Pharmaceutical Co., Ltd. - Euroscreen S.A. - Applied NeuroSolutions, Inc. - Avineuro Pharmaceuticals, Inc. - Panacea Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - Novartis AG - Isotechnika Pharma Inc. - Samyang Corporation - Aphios Corporation - Alzhyme Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - H Lundbeck A/S - Jeil Pharmaceutical Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier For more information visit http://www.researchandmarkets.com/research/d9h2c7/alzheimers
